AL
OMED

Airain Ltd’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Airain Ltd’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,208
Closed -$212K – 1098
2014
Q3 		$212K Buy
+11,208
New +$225K 0.01% 666

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Apex Capital Orinda, California $938M AUM 4.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Airain Ltd's OMED Position: Q4 2014 in Review

Airain Ltd sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2014, closing a stake of 11,208 shares — an estimated $212K sold.

Airain Ltd first reported a position in OMED in Q3 2014 and held it in 1 quarter. The position peaked at $212K in Q3 2014. 68 funds tracked by Wall St. Rank hold OMED as of Q4 2014.

  • Airain Ltd reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Airain Ltd sold 11,208 OncoMed Pharmaceuticals, Inc. shares in Q4 2014, an estimated $212K.
  • Airain Ltd first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • Airain Ltd's OncoMed Pharmaceuticals, Inc. position peaked at $212K in Q3 2014.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2014.

Based on Airain Ltd's 13F filing for Q4 2014, filed 12 Feb 2015.